$1.96-0.8%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
Company outlook: revenue of $155M to $160M for Fiscal year 2026 — down 1.6% on a year earlier ($160M)
Just reported
From Pacific Biosciences of California, Inc.'s results release of November 4, 2026; its quarterly report has since been filed.
Actual
$40.6M
+5.5% y/y
+4.0% q/q
Guided
—
No guide given
Actual
-$0.12
Guided
—
No guide given
Actual
-$37M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $40.6M | $38.4M | +5.52% |
| Profit | -$37.8M | -$38M | +0.41% |
| Profit per share | -$0.12 | -$0.13 | +7.69% |
| Free Cash Flow | -$38.6M | -$18.6M | -107.26% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Pacific Biosciences of California, Inc. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“PacBio is entering an exciting phase as the investments we’ve made in our technology begin to unlock new opportunities,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which consist of our HiFi long-read sequencing systems, address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Pacific Biosciences of California, Inc.’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.